1. Home
  2. BEAM vs BHE Comparison

BEAM vs BHE Comparison

Compare BEAM & BHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$32.75

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Benchmark Electronics Inc.

BHE

Benchmark Electronics Inc.

HOLD

Current Price

$85.52

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
BHE
Founded
2017
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Electrical Products
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.1B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
BEAM
BHE
Price
$32.75
$85.52
Analyst Decision
Buy
Strong Buy
Analyst Count
12
3
Target Price
$50.75
$55.00
AVG Volume (30 Days)
2.6M
569.0K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
0.94%
EPS Growth
82.31
N/A
EPS
N/A
0.36
Revenue
$24,000.00
$2,659,108,000.00
Revenue This Year
N/A
$7.03
Revenue Next Year
$33.77
$6.57
P/E Ratio
N/A
$236.83
Revenue Growth
33.33
0.11
52 Week Low
$15.60
$34.44
52 Week High
$38.26
$100.41

Technical Indicators

Market Signals
Indicator
BEAM
BHE
Relative Strength Index (RSI) 48.29 46.59
Support Level $23.83 $80.52
Resistance Level $35.18 $88.27
Average True Range (ATR) 2.84 4.62
MACD -0.06 -1.48
Stochastic Oscillator 21.32 33.14

Price Performance

Historical Comparison
BEAM
BHE

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.

Share on Social Networks: